生物可吸收支架与药物洗脱支架治疗冠状动脉小血管病变的比较研究-东南大学学报医学版

生物可吸收支架与药物洗脱支架治疗冠状动脉小血管病变的比较研究

单位：福建医科大学公共卫生学院卫生管理学系, 福建福州 350122

分类号：R816.2;R543.3

出版年·卷·期（页码）：2022·41·第一期（26-34）

摘要：

目的：系统评价生物可吸收支架（BVS）与药物洗脱支架（DES）治疗冠状动脉小血管病变的安全性和有效性。方法：系统检索PubMed、中国知网、万方等数据库中对比BVS与DES的随机对照试验研究文献，时间跨度为2009年1月至2020年3月。根据改良Jadad量表评价文献质量。采用RevMan 5.3软件进行Meta分析。结果：最终纳入8个研究，共6 352例患者（BVS组3 582例，DES组2 770例）。Meta分析结果表明，两组支架置入后随访期内的心血管不良事件发生率、靶病变血运重建率差异有统计学意义（P=0.05、P=0.007），全因死亡率、支架内血栓形成率、心源性死亡率差异无统计学意义（P=0.07、P=0.17、P=0.90）。结论：基于目前获得的证据显示，BVS组的安全性和有效性并不显著优于DES组，但是纳入研究具有一定的偏倚风险，本研究结论需进一步严格的临床对照试验证明。

Objective: To systematically evaluate the safety and efficacy of bioresorbable vascular scaffolds(BVS) and drug-eluting stents(DES) in the treatment of coronary artery small vessel disease. Methods: PubMed, Chinese National Knowledge Infrastructure and Wanfang databases were searched to collect literature of randomized controlled trials comparing BVS and DES published from January 2009 to March 2020. The quality of the literature was evaluated according to the modified Jadad scale. Meta-analysis was performed with software RevMan 5.3. Results: Eight randomized controlled clinical trials involving 6 352 patients(3 582 cases in BVS group and 2 770 cases in DES group) were included. Meta-analysis showed that there were significant differences on major adverse cardiac events, target lesion revascularization rate(P=0.05,P=0.007), and there were not significant differences on all-cause mortality, stent thrombosis rate, cardiogenic mortality(P=0.07,P=0.17,P=0.90). Conclusion: Based on the currently available evidence, the safety and effectiveness in the BVS group are not significantly better than those in the DES group. However, the included studies have a certain risk of bias, and the conclusions of this study need further rigorously controlled clinical trials to prove.

参考文献：

[1] 张晓群, 王启闻, 汪欣, 等.不同药物洗脱支架对冠状动脉小血管病变患者预后影响的meta分析[J].浙江大学学报(医学版), 2017, 46(3):305-314.
[2] 唐元升, 刘同宝.冠状动脉小血管病变的介入治疗[J].山东医药, 2002, 42(20):62-63.
[3] FIHN S D, GARDIN J M, ABRAMS J, et al.2012 ACCF/ACC/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons[J].J Am Coll Cardiol, 2012, 60(24):e44-e164.
[4] MONTALESCOT G, SECHTEM U, ACHENBACH S, et al.2013 ESC guidelines on the management of stable coronary artery disease:The Task Force on the management of stable coronary artery disease of the European Society of Cardiology[J].Eur Heart J, 2013, 34(38):2949-3003.
[5] GAO R L, YANG Y J, HAN Y L, et al.Bioresorbable vascular scaffolds versus metallic stents in patients with coronary artery disease:ABSORB China Trial[J].J Am Coll Cardiol, 2015, 66(21):2298-2309.
[6] WIEBE J, NEF H M, HAMM C W.Current status of bioresorbable scaffolds in the treatment of coronary artery disease[J].J Am Coll Cardiol, 2014, 64(23):2541-2551.
[7] KEREIAKES D J, ELLIS S G, POPMA J J, et al.Evaluation of a fully bioresorbable vascular scaffold in patients with coronary artery disease:design of and rationale for the ABSORB III randomized trial[J].Am Heart J, 2015, 170(4):641-651.
[8] KIMURA T, KOZUMA K, TANABE K, et al.A randomized trial evaluating everolimus-eluting ABSORB bioresorbable scaffolds vs.everolimus-eluting metallic stents in patients with coronary artery disease:ABSORB Japan[J].Eur Heart J, 2015, 36(47):3332-3342.
[9] PURICEL S, ARROYO D, CORPATAUX N, et al.Comparison of everolimus-and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds[J].J Am Coll Cardiol, 2015, 65(8):791-801.
[10] KATAGIRI Y, STONE G W, ONUMA Y, et al.State of the art:the inception, advent and future of fully bioresorbable scaffolds[J].EuroIntervention, 2017, 13(6):734-750.
[11] SERRUYS P W, GARCIA-GARCIA H M, ONUMA Y.From metallic cages to transient bioresorbable scaffolds:change in paradigm of coronary revascularization in the upcoming decade?[J].Eur Heart J, 2012, 33(1):16-25.
[12] ZHANG Y J, GAO R L, XU B, et al.Bioresorbable scaffolds for coronary artery disease:current status and future prospective[J].Chinese Medical Journal, 2014, 127(6):1141-1148.
[13] ZHANG Y J, BOURANTAS C V, FAROOQ V, et al.Bioresorbable scaffolds in the treatment of coronary artery disease[J].Med Devices(Auckl), 2013, 6:37-48.
[14] 梁宇博, 林欣, 车千秋, 等.经皮冠状动脉介入治疗术中应用生物可吸收支架的安全性和有效性的系统评价[J].中国循证心血管医学杂志, 2019, 11(2):148-154.
[15] 任昊, 黎荣克, 王刃.血管内生物可吸收支架现状与挑战[J].中国生物医学工程学报, 2017, 36(3):354-359.
[16] TOGNI M, EBER S, WIDMER J, et al.Impact of vessel size on outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents:a subgroup analysis of the SIRTAX trial[J].J Am Coll Cardiol, 2007, 50(12):1123-1131.
[17] ARROYO D, GENDRE G, SCHUKRAFT S, et al.Comparison of everolimus-and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds:two-year clinical outcomes of the EVERBIO Ⅱ Trial[J].Int J Cardiol, 2017, 243:121-125.
[18] KEREIAKES D J, ELLIS S G, METZGER C, et al.3-year clinical outcomes with everolimus-eluting bioresorbable coronary scaffolds:the ABSORB Ⅲ Trial[J].J Am Coll Cardiol, 2017, 70(23):2852-2862.
[19] KEREIAKES D J, MEREDITH I T, WINDECKER S, et al.Efficacy and safety of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent:the Evolve Ii Randomized Trial[J].Circ Cardiovasc Interv, 2015, 8(4):e002372.
[20] KIM S H, KANG S H, LEE J M, et al.Three-year clinical outcome of biodegradable hybrid polymer orsiro sirolimus-eluting stent and the durable biocompatible polymer resolute integrity zotarolimus-eluting stent:a Randomized Controlled Trial[J].Catheter Cardiovasc Interv, 2020, 96(7):1399-1406.
[21] SERRUYS P W, KATAGIRI Y, SOTOMI Y, et al.Arterial remodeling after bioresorbable scaffolds and metallic stents[J].J Am Coll Cardiol, 2017, 70(1):60-74.
[22] SUWANNASOM P, SOTOMI Y, ISHIBASHI Y, et al.The impact of post-procedural asymmetry, expansion, and eccentricity of bioresorbable everolimus-eluting scaffold and metallic everolimus-eluting stent on clinical outcomes in the Absorb Ii Trial[J].JACC Cardiovasc Interv, 2016, 9(12):1231-1242.
[23] 纪兆乐.生物可吸收支架与药物洗脱支架植入术后炎症反应的比较[D].西安:第四军医大学, 2016.
[24] HAN Y L, XU B, FU G S, et al.A randomized trial comparing the neovas sirolimus-eluting bioresorbable?Scaffold and metallic?Everolimus-eluting stents[J].JACC Cardiovasc Interv, 2018, 11(3):260-272.
[25] SERRUYS P W, CHEVALIER B, DUDEK D, et al.A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions(ABSORB Ⅱ):an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial[J].Lancet, 2015, 385(9962):43-54.
[26] 聂毛晓, 赵全明.生物可吸收支架临床研究进展及应用前景[J].中国循证心血管医学杂志, 2018, 10(3):370-371, 373.
[27] BRUGALETTA S, RADU M D, GARCIA-GARCIA H M, et al.Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation:can the scaffold cap the plaque?[J].Atherosclerosis, 2012, 221(1):106-112.
[28] WAKSMAN R.Biodegradable stents:they do their job and disappear[J].J Invasive Cardiol, 2006, 18(2):70-74.
[29] 高旸, 丁嵩, 何奔.生物可吸收支架在经皮冠状动脉介入治疗中的应用现状[J].中国介入心脏病学杂志, 2017, 25(3):163-165.
[30] LELASI A, TESPILI M.Current and future perspectives on drug eluting bioresorbable coronary scaffolds[J].Future Cardiol, 2014, 10(3):409-420.
[31] STONE G W, ELLIS S G, COX D A.A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease[J].N Engl J Med, 2004, 350(3):221-231.
[32] APPLEGATE R, HERMILLER J, WILLIAMS J, et al.Evaluation of the effects of everolimus-eluting and paclitaxel-eluting stents on target lesions with jailed side branches:2-year results from the SPIRIT Ⅲ randomized trial[J].Catheter Cardiovasc Interv, 2010, 76(5):644-651.
[33] NAKATANI S, NISHINO M, TANIIKE M, et al.Initial findings of impact of strut width on stent coverage and apposition of sirolimus-eluting stents assessed by optical coherence tomography[J].Catheter Cardiovasc Interv, 2013, 81(5):776-781.
[34] 柯俊松.生物可吸收支架与第二代药物洗脱支架在ST段抬高型心肌梗死治疗中的安全性和有效性Meta分析[D].南昌:南昌大学, 2020.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录